These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 19901101)
1. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. DeAngelis LM J Clin Oncol; 2009 Dec; 27(35):5861-2. PubMed ID: 19901101 [No Abstract] [Full Text] [Related]
2. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110 [TBL] [Abstract][Full Text] [Related]
3. Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas. Wick W; Winkler F Cancer; 2018 Jul; 124(13):2674-2676. PubMed ID: 29698549 [No Abstract] [Full Text] [Related]
4. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104 [TBL] [Abstract][Full Text] [Related]
5. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV. Levin VA Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490 [No Abstract] [Full Text] [Related]
6. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. Schiff D Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745 [TBL] [Abstract][Full Text] [Related]
7. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Rinne ML; Wen PY Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491 [No Abstract] [Full Text] [Related]
8. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? Wen PY J Clin Oncol; 2010 Apr; 28(12):1977-9. PubMed ID: 20308652 [No Abstract] [Full Text] [Related]
9. [Clinicopathological diagnosis of gliomas by genotype analysis]. Nakamura M; Shimada K; Nakase H; Konishi N Brain Nerve; 2009 Jul; 61(7):773-80. PubMed ID: 19618854 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640 [TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844 [TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy for malignant gliomas]. Nagane M No Shinkei Geka; 2007 May; 35(5):433-50. PubMed ID: 17491340 [No Abstract] [Full Text] [Related]
13. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062 [TBL] [Abstract][Full Text] [Related]
15. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856 [TBL] [Abstract][Full Text] [Related]
16. Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy. Baumert BG; Stupp R; ; Ann Oncol; 2008 Sep; 19 Suppl 7():vii217-22. PubMed ID: 18790954 [No Abstract] [Full Text] [Related]
17. Prime time for molecular marker diagnostics in neuro-oncology. Weller M; Stupp R Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956 [No Abstract] [Full Text] [Related]
18. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
19. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778 [TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy for brain tumors in adult patients]. Weller M Nervenarzt; 2008 Feb; 79(2):231-41. PubMed ID: 18253773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]